Document Type

Journal Article

Publication Date

1-18-2013

Journal

BJOG: An International Journal of Obstetrics and Gynaecology

Volume

Volume 120, Issue 10

Inclusive Pages

1183-1191

Keywords

Antigens, CD--blood; Pre-Eclampsia--blood; Pregnancy Proteins--blood; Pregnancy Trimester, First--blood; Pregnancy Trimester, Second--blood; Receptors, Cell Surface--blood; Vascular Endothelial Growth Factor Receptor-1--blood

Abstract

OBJECTIVE:

To determine if change in maternal angiogenic biomarkers between the first and second trimesters predicts pre-eclampsia in low-risk nulliparous women.

DESIGN:

A nested case-control study of change in maternal plasma soluble Flt-1 (sFlt-1), soluble endoglin (sEng) and placenta growth factor (PlGF). We studied 158 pregnancies complicated by pre-eclampsia and 468 normotensive nonproteinuric controls.

SETTING:

A multicentre study in 16 academic medical centres in the USA.

POPULATION:

Low-risk nulliparous women.

METHODS:

Luminex assays for PlGF, sFlt-1 and sEng performed on maternal EDTA plasma collected at 9-12, 15-18 and 23-26 weeks of gestation. Rate of change of analyte between first and either early or late second trimester was calculated with and without adjustment for baseline clinical characteristics.

MAIN OUTCOME MEASURES:

Change in PlGF, sFlt-1 and sEng.

RESULTS:

Rates of change of PlGF, sEng and sFlt-1 between first and either early or late second trimesters were significantly different in women who developed pre-eclampsia, severe pre-eclampsia or early-onset pre-eclampsia compared with women who remained normotensive. Inclusion of clinical characteristics (race, body mass index and blood pressure at entry) increased sensitivity for detecting severe and particularly early-onset pre-eclampsia but not pre-eclampsia overall. Receiver operating characteristics curves for change from first to early second trimester in sEng, PlGF and sFlt-1 with clinical characteristics had areas under the curve of 0.88, 0.84 and 0.86, respectively, and for early-onset pre-eclampsia with sensitivities of 88% (95% CI 64-99), 77% (95% CI 50-93) and 77% (95% CI 50-93) for 80% specificity, respectively. Similar results were seen in the change from first to late second trimester.

CONCLUSION:

Change in angiogenic biomarkers between first and early second trimester combined with clinical characteristics has strong utility for predicting early-onset pre-eclampsia.

Comments

This article is a U.S. Government work and is in the public domain in the USA.

Originally published in BJOG: An International Journal of Obstetrics and Gynaecology.

Creative Commons License

Creative Commons License
This work is free of known copyright restrictions.

Peer Reviewed

1

Open Access

1

Share

COinS